The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CEFOTAXIME SODIUM     sodium(6S,7S)-3- (acetyloxymethyl)-7...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CEFOTAXIME SODIUM


Psychiatry related information on CEFOTAXIME SODIUM


High impact information on CEFOTAXIME SODIUM

  • Patients treated with cefotaxime had higher levels of plasma renin activity than those treated with cefotaxime and albumin; patients with renal impairment had the highest values [3].
  • By 12 hours after the beginning of therapy, the mean opening cerebrospinal pressure and the estimated cerebral perfusion pressure had improved significantly in the dexamethasone-treated children but worsened in the children treated only with cefotaxime (controls) [1].
  • Three cycles of shuffling and two cycles of backcrossing with wild-type DNA, to eliminate non-essential mutations, were each followed by selection on increasing concentrations of the antibiotic cefotaxime [7].
  • Cefotaxime failure in group A streptococcal meningitis [8].
  • Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis [9].

Chemical compound and disease context of CEFOTAXIME SODIUM


Biological context of CEFOTAXIME SODIUM


Anatomical context of CEFOTAXIME SODIUM


Associations of CEFOTAXIME SODIUM with other chemical compounds



  • Nucleotide sequences of the pbpX genes encoding the penicillin-binding proteins 2x from Streptococcus pneumoniae R6 and a cefotaxime-resistant mutant, C506 [26].
  • The G238S substitution found in extended-spectrum natural mutants of TEM-1 beta-lactamase induces a new capacity to hydrolyze cefotaxime and a large loss of activity against the good substrates of TEM-1 [27].
  • Early log MIC cefotaxime or faropenem-treated bacteria also enhanced TLR2 activation by 3-fold and 4-fold, respectively, when compared with untreated bacteria [28].
  • The lower concentration of cefotaxime reduced the LPS-stimulated IL-8 levels [29].
  • Conclusion: These results indicate a modulation of the expression density of CD14 on monocytes, together with a shift from a balanced to an inflammatory cytokine release pattern, by cefuroxime and cefotaxime [30].

Analytical, diagnostic and therapeutic context of CEFOTAXIME SODIUM


  1. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. Odio, C.M., Faingezicht, I., Paris, M., Nassar, M., Baltodano, A., Rogers, J., Sáez-Llorens, X., Olsen, K.D., McCracken, G.H. N. Engl. J. Med. (1991) [Pubmed]
  2. Endocarditis due to Streptococcus mitis with high-level resistance to penicillin and cefotaxime. Lonks, J.R., Dickinson, B.P., Runarsdottir, V. N. Engl. J. Med. (1999) [Pubmed]
  3. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. Sort, P., Navasa, M., Arroyo, V., Aldeguer, X., Planas, R., Ruiz-del-Arbol, L., Castells, L., Vargas, V., Soriano, G., Guevara, M., Ginès, P., Rodés, J. N. Engl. J. Med. (1999) [Pubmed]
  4. Relapse of gram-negative bacillary meningitis after cefotaxime therapy. Bradsher, R.W. JAMA (1982) [Pubmed]
  5. Cefotaxime therapy in children with serious infections associated with reduced host defense mechanisms. López, E.L., Bonesana, N.F., Rubeglio, E., Schugurensky, A., Sommersguter, G., Grinstein, S. J. Antimicrob. Chemother. (1980) [Pubmed]
  6. Single-dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial. Repetto, H.A., MacLoughlin, G.J. J. Antimicrob. Chemother. (1984) [Pubmed]
  7. Rapid evolution of a protein in vitro by DNA shuffling. Stemmer, W.P. Nature (1994) [Pubmed]
  8. Cefotaxime failure in group A streptococcal meningitis. Bass, J.W. JAMA (1983) [Pubmed]
  9. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Navasa, M., Follo, A., Llovet, J.M., Clemente, G., Vargas, V., Rimola, A., Marco, F., Guarner, C., Forné, M., Planas, R., Bañares, R., Castells, L., Jimenez De Anta, M.T., Arroyo, V., Rodés, J. Gastroenterology (1996) [Pubmed]
  10. Intravenous cefotaxime in children with bacterial meningitis. Belohradsky, B.H., Bruch, K., Geiss, D., Kafetzis, D., Marget, W., Peters, G. Lancet (1980) [Pubmed]
  11. Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial. Smith, C.R., Ambinder, R., Lipsky, J.J., Petty, B.G., Israel, E., Levitt, R., Mellits, E.D., Rocco, L., Longstreth, J., Lietman, P.S. Ann. Intern. Med. (1984) [Pubmed]
  12. Prevention of infection in critically ill patients by selective decontamination of the digestive tract. Cockerill, F.R., Muller, S.R., Anhalt, J.P., Marsh, H.M., Farnell, M.B., Mucha, P., Gillespie, D.J., Ilstrup, D.M., Larson-Keller, J.J., Thompson, R.L. Ann. Intern. Med. (1992) [Pubmed]
  13. Pneumococcal resistance to antibiotics. Klugman, K.P. Clin. Microbiol. Rev. (1990) [Pubmed]
  14. Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients. Ariza, J., Xiol, X., Esteve, M., Fernández Bañeres, F., Liñares, J., Alonso, T., Gudiol, F. Hepatology (1991) [Pubmed]
  15. Triple regimen of selective decontamination of the digestive tract, systemic cefotaxime, and microbiological surveillance for prevention of acquired infection in intensive care. Ledingham, I.M., Alcock, S.R., Eastaway, A.T., McDonald, J.C., McKay, I.C., Ramsay, G. Lancet (1988) [Pubmed]
  16. Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type beta-lactamases probed by site-directed mutagenesis and three-dimensional modeling. Huletsky, A., Knox, J.R., Levesque, R.C. J. Biol. Chem. (1993) [Pubmed]
  17. Characterization of TEM-1 beta-lactamase mutants from positions 238 to 241 with increased catalytic efficiency for ceftazidime. Venkatachalam, K.V., Huang, W., LaRocco, M., Palzkill, T. J. Biol. Chem. (1994) [Pubmed]
  18. Kinetics of beta-lactam interactions with penicillin-susceptible and -resistant penicillin-binding protein 2x proteins from Streptococcus pneumoniae. Involvement of acylation and deacylation in beta-lactam resistance. Lu, W.P., Kincaid, E., Sun, Y., Bauer, M.D. J. Biol. Chem. (2001) [Pubmed]
  19. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Brun-Buisson, C., Legrand, P., Philippon, A., Montravers, F., Ansquer, M., Duval, J. Lancet (1987) [Pubmed]
  20. Penetration of cefotaxime into pancreatic juice. Benveniste, G.L., Morris, R.G. Lancet (1985) [Pubmed]
  21. Intracellular replication is essential for the virulence of Salmonella typhimurium. Leung, K.Y., Finlay, B.B. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  22. Emerging role of cephalosporins in bacterial meningitis. Nelson, J.D. Am. J. Med. (1985) [Pubmed]
  23. In-vitro activity of new cephalosporin (HR 756) and cefazolin. Stratford, B.C. Lancet (1978) [Pubmed]
  24. In-vitro activity of new cephalosporin (HR 756) and cefazolin. Vanhoff, R., Butzler, J.P., Yourassowsky, E. Lancet (1978) [Pubmed]
  25. Mutations in the active site of penicillin-binding protein PBP2x from Streptococcus pneumoniae. Role in the specificity for beta-lactam antibiotics. Mouz, N., Di Guilmi, A.M., Gordon, E., Hakenbeck, R., Dideberg, O., Vernet, T. J. Biol. Chem. (1999) [Pubmed]
  26. Nucleotide sequences of the pbpX genes encoding the penicillin-binding proteins 2x from Streptococcus pneumoniae R6 and a cefotaxime-resistant mutant, C506. Laible, G., Hakenbeck, R., Sicard, M.A., Joris, B., Ghuysen, J.M. Mol. Microbiol. (1989) [Pubmed]
  27. Mass spectral kinetic study of acylation and deacylation during the hydrolysis of penicillins and cefotaxime by beta-lactamase TEM-1 and the G238S mutant. Saves, I., Burlet-Schiltz, O., Maveyraud, L., Samama, J.P., Promé, J.C., Masson, J.M. Biochemistry (1995) [Pubmed]
  28. The glycopeptide vancomycin does not enhance toll-like receptor 2 (TLR2) activation by Streptococcus pneumoniae. Moore, L.J., Pridmore, A.C., Dower, S.K., Read, R.C. J. Antimicrob. Chemother. (2004) [Pubmed]
  29. Effect of RO 23-9424, cefotaxime and fleroxacin on functions of human polymorphonuclear cells and cytokine production by human monocytes. Matera, G., Berlinghieri, M.C., Foti, F., Barreca, G.S., Focà, A. J. Antimicrob. Chemother. (1996) [Pubmed]
  30. Antibiotics modulate the stimulated cytokine response to endotoxin in a human ex vivo, in vitro model. Ziegeler, S., Raddatz, A., Hoff, G., Buchinger, H., Bauer, I., Stockhausen, A., Sasse, H., Sandmann, I., Hörsch, S., Rensing, H. Acta anaesthesiologica Scandinavica. (2006) [Pubmed]
  31. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Rimola, A., Salmerón, J.M., Clemente, G., Rodrigo, L., Obrador, A., Miranda, M.L., Guarner, C., Planas, R., Solá, R., Vargas, V. Hepatology (1995) [Pubmed]
  32. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Moore, R.D., Smith, C.R., Lietman, P.S. Am. J. Med. (1986) [Pubmed]
  33. Comparison of intravenous ciprofloxacin and intravenous cefotaxime for antimicrobial prophylaxis in transurethral surgery. Cox, C.E. Am. J. Med. (1989) [Pubmed]
WikiGenes - Universities